China National Medicines Inkomsten in het verleden

Verleden criteriumcontroles 4/6

China National Medicines is de winst gegroeid met een gemiddeld jaarlijks percentage van 9.1%, terwijl de Healthcare industrie de winst jaarlijks groeide met 2%. De inkomsten zijn gegroeid met een gemiddelde snelheid van 4% per jaar. Het rendement op eigen vermogen van China National Medicines is 12.6%, en het heeft een nettomarge van 4.2%.

Belangrijke informatie

9.1%

Groei van de winst

9.3%

Groei van de winst per aandeel

Healthcare Groei van de industrie	7.0%
Inkomstengroei	4.0%
Rendement op eigen vermogen	12.6%
Nettomarge	4.2%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28

Opbrengsten en kosten

Hoe China National Medicines geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SHSE:600511 Opbrengsten, kosten en inkomsten (CNY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	51,195	2,165	1,337	62
30 Jun 24	50,312	2,162	1,351	66
31 Mar 24	50,592	2,191	1,417	68
31 Dec 23	49,696	2,146	1,437	71
30 Sep 23	47,486	1,995	1,416	76
30 Jun 23	47,632	2,086	1,476	72
31 Mar 23	45,665	2,005	1,428	70
31 Dec 22	45,499	1,964	1,385	67
30 Sep 22	46,719	1,884	1,413	60
30 Jun 22	46,399	1,850	1,385	59
31 Mar 22	47,185	1,830	1,394	57
31 Dec 21	46,469	1,754	1,390	56
30 Sep 21	45,559	1,680	1,394	56
30 Jun 21	44,923	1,529	1,435	55
31 Mar 21	42,512	1,449	1,445	53
31 Dec 20	40,379	1,383	1,413	52
30 Sep 20	41,046	1,537	1,426	62
30 Jun 20	41,153	1,469	1,418	52
31 Mar 20	42,805	1,549	1,415	50
31 Dec 19	44,644	1,604	1,489	45
30 Sep 19	42,673	1,525	1,443	42
30 Jun 19	40,991	1,523	1,414	42
31 Mar 19	39,659	1,436	1,424	37
31 Dec 18	38,740	1,404	1,457	34
30 Sep 18	37,994	1,256	1,424	22
30 Jun 18	37,452	1,224	1,363	30
31 Mar 18	36,653	1,163	1,176	25
31 Dec 17	36,285	1,141	1,002	22
30 Sep 17	36,072	1,060	918	10
30 Jun 17	35,540	1,044	823	0
31 Mar 17	40,103	1,101	967	0
31 Dec 16	34,611	990	851	0
30 Sep 16	28,613	887	675	0
30 Jun 16	22,813	752	594	0
31 Mar 16	12,408	527	385	0
31 Dec 15	12,078	513	381	0
30 Sep 15	12,065	499	415	0
30 Jun 15	11,894	499	385	0
31 Mar 15	11,773	490	397	0
31 Dec 14	11,538	483	390	0
30 Sep 14	11,177	465	391	0
30 Jun 14	10,824	457	388	0
31 Mar 14	10,408	431	366	0
31 Dec 13	10,081	412	359	0

Kwaliteitswinsten: 600511 heeft hoge kwaliteitsinkomsten.

Groeiende winstmarge: De huidige netto winstmarges (4.2%) 600511 } zijn hoger dan vorig jaar (4.2%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van 600511 is de afgelopen 5 jaar met 9.1% per jaar gegroeid.

Versnelling van de groei: De winstgroei van 600511 over het afgelopen jaar ( 8.5% ) ligt onder het 5-jarig gemiddelde ( 9.1% per jaar).

Winst versus industrie: De winstgroei 600511 over het afgelopen jaar ( 8.5% ) overtrof de Healthcare -sector -5.7%.

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 12.6% ) van 600511 wordt als laag beschouwd.

China National Medicines Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings released: EPS: CN¥0.64 (vs CN¥0.63 in 3Q 2023)

China National Medicines Corporation Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Second quarter 2024 earnings released: EPS: CN¥0.72 (vs CN¥0.76 in 2Q 2023)

China National Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 22, 2024

First quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in 1Q 2023)

China National Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Recent updates

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Third quarter 2024 earnings released: EPS: CN¥0.64 (vs CN¥0.63 in 3Q 2023)

China National Medicines Corporation Ltd. to Report Q3, 2024 Results on Oct 24, 2024

Investor sentiment improves as stock rises 16%

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Now 22% undervalued after recent price drop

Second quarter 2024 earnings released: EPS: CN¥0.72 (vs CN¥0.76 in 2Q 2023)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Now 21% undervalued after recent price drop

Now 21% undervalued after recent price drop

China National Medicines Corporation Ltd. to Report First Half, 2024 Results on Aug 22, 2024

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Now 20% undervalued

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Dividend increased to CN¥0.85

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

First quarter 2024 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in 1Q 2023)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines Corporation Ltd. to Report Q1, 2024 Results on Apr 26, 2024

China National Medicines Corporation Ltd., Annual General Meeting, Apr 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

China National Medicines (SHSE:600511) Could Easily Take On More Debt

China National Medicines Corporation Ltd. to Report Fiscal Year 2023 Results on Mar 21, 2024

Third quarter 2023 earnings released: EPS: CN¥0.63 (vs CN¥0.76 in 3Q 2022)

China National Medicines Corporation Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.76 (vs CN¥0.65 in 2Q 2022)

Price target increased by 14% to CN¥46.58

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.76 (vs CN¥0.71 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.65 (vs CN¥0.62 in 2Q 2021)

China National Medicines Corporation Ltd.(XSSC:600511) dropped from S&P Global BMI Index

China National Medicines Corporation Ltd.(XSSC:600511) dropped from FTSE All-World Index (USD)

Price target decreased to CN¥39.20

Less than half of directors are independent

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Now 23% undervalued after recent price drop

Third quarter 2021 earnings released: EPS CN¥0.71 (vs CN¥0.51 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.62 (vs CN¥0.51 in 2Q 2020)

Upcoming dividend of CN¥0.55 per share

First quarter 2021 earnings released: EPS CN¥0.40 (vs CN¥0.31 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.83 (vs CN¥2.11 in FY 2019)

New 90-day low: CN¥36.33

New 90-day low: CN¥41.32

China National Medicines Corporation Ltd. to Report Fiscal Year 2020 Results on Mar 19, 2021

China National Medicines Corporation Ltd. Announces Resignation of Li Hui as A Director, the General Manager, A Member of the Strategy Committee and A Member of the Audit Committee

Investor sentiment deteriorated over the past week

Market bids up stock over the past week

New 90-day high: CN¥50.10

Third quarter earnings released

China National Medicines Corporation Ltd. to Report Q3, 2020 Results on Oct 22, 2020

Earnings released

New 90-day high - CN¥52.00

China National Medicines Corporation Ltd. to Report First Half, 2020 Results on Aug 19, 2020

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden